Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial - Boscaro, M; Ludlam, W H; Atkinson, B; Glusman, J E; Petersenn, S; Reincke, M; Snyder, P; Tabarin, A; Biller, B M; Findling, J; Melmed, S; Darby, C H; Hu, K; Wang, Y; Freda, P U; Grossman, A B; Frohman, L A; Bertherat, J (J Clin Endocrinol Metab, 2009)